Research Site

Patchogue, New York 11772

1 studies enrolling now · 21 studies all time

What they study most

Alzheimer's Disease, Cardiovascular Disease, Generalized Myasthenia Gravis, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Progressive Cognitive Decline, Relapsing Forms of Multiple Sclerosis, Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis

Studies at this site

• A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event — Recruiting now
• Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis — Running, not enrolling
• Evaluation of Natalizumab for thE Relief of MS Associated FatiGue — Completed
• Dimethyl Fumarate (DMF) Observational Study — Completed
• Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) — Stopped early
• BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) — Completed
• Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera — Completed
• Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants — Completed
• Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) — Completed
• BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis — Completed
• Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States — Completed
• Rebif® Rebidose® Versus Rebiject II® Ease-of-Use — Completed
• The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis — Completed
• JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab — Completed
• Tecfidera Lymphocyte Chart Review — Completed
• Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline — Completed
• Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS — Completed
• Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis — Completed
• Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis — Stopped early
• Treatment Interruption of Natalizumab — Completed
• Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline — Completed